Does clinical trial subject selection restrict the ability to generalize use and cost of health services to "real life" subjects?
Subject differences may impede generalizing from RCTs to real life.
Neither the RF nor anti-CCP antibody status in RA patients is associated with a clinical response to anti-TNFα treatment.